322 related articles for article (PubMed ID: 33716988)
1. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs.
Yuen KCJ; Miller BS; Boguszewski CL; Hoffman AR
Front Endocrinol (Lausanne); 2021; 12():637209. PubMed ID: 33716988
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Miller BS; Velazquez E; Yuen KCJ
J Clin Endocrinol Metab; 2020 Jun; 105(6):e2121-33. PubMed ID: 31676901
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency.
Pampanini V; Deodati A; Inzaghi E; Cianfarani S
Horm Res Paediatr; 2023; 96(6):553-559. PubMed ID: 35220308
[TBL] [Abstract][Full Text] [Related]
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
[No Abstract] [Full Text] [Related]
5. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
6. The current state of long-acting growth hormone preparations for growth hormone therapy.
Yuen KCJ; Miller BS; Biller BMK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):267-273. PubMed ID: 29746309
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
[TBL] [Abstract][Full Text] [Related]
8. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks.
Höybye C
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101788. PubMed ID: 37308376
[TBL] [Abstract][Full Text] [Related]
9. Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk.
Boguszewski CL
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101817. PubMed ID: 37643936
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
11. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
12. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
13. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products.
Velazquez EP; Miller BS; Yuen KCJ
Expert Rev Endocrinol Metab; 2024; 19(1):1-10. PubMed ID: 38112103
[TBL] [Abstract][Full Text] [Related]
14. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
16. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
17. Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M; Biller BMK; Clemmons D; Jørgensen JOL; Nishioka H; Takahashi Y
Front Endocrinol (Lausanne); 2022; 13():1040046. PubMed ID: 36619571
[TBL] [Abstract][Full Text] [Related]
18. Adult growth hormone deficiency: clinical advances and approaches to improve adherence.
Yuen KCJ; Llahana S; Miller BS
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):419-436. PubMed ID: 31721610
[No Abstract] [Full Text] [Related]
19. Update on the use of long-acting growth hormone in children.
Boguszewski MCDS; Boguszewski CL
Curr Opin Pediatr; 2024 Aug; 36(4):437-441. PubMed ID: 38747211
[TBL] [Abstract][Full Text] [Related]
20. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]